MTHFR and ABCB1 polymorphisms associated with toxicity in hematological malignancies patients receiving high dose methotrexate
High-dose methotrexate(HD-MTX) has been used in clinical treatment of hematological malignancies and toxicity appeared at the same time. Gene polymorphisms may participate in the activity of MTX-related enzymes and induce drug-related toxicity. The influence of MTHFR C677T, MTHFR A1298C and ABCB1 C3435T polymorphisms on the MTX-related toxicity and delay elimination in adult with hematological malignancies is controversial. Here, a total of 111 patients were analyzed. MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are related to MTX-related toxicity in adults with hematological malignancies. Age(≥ 60 years) and MTHFR 1298AC were identified as independent risk factors for delayed elimination of MTX. This reminds us that the MTHFR C677T, MTHFR A1298C and ABCB1 C3435T gene polymorphisms are expected to be a useful tool in reducing toxicity and improving outcome in personalized HD-MTX therapy for patients with hematological malignancies.
Authors
- Peng Zhang
- Dan Zhang (ORCID: https://orcid.org/0000-0001-9792-4549)
- Hui Wang (ORCID: https://orcid.org/0000-0002-2454-3814)
- Nan Zhou (ORCID: https://orcid.org/0000-0001-5091-5688)
- Yaling Shi
- Lu Cao (ORCID: https://orcid.org/0000-0001-5893-5085)
Institutions
- Shanxi Medical University (CN)
- Shanxi Provincial People’s Hospital (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1038/s41598-025-33039-x
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shaanxi Provincial Science and Technology Department
- Shaanxi Science and Technology Association